Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UK05
UPID:
GDF2_HUMAN
Alternative names:
Bone morphogenetic protein 9
Alternative UPACC:
Q9UK05; Q5VSQ9; Q9Y571
Background:
Growth/differentiation factor 2, also known as Bone morphogenetic protein 9, is a potent circulating inhibitor of angiogenesis. It uniquely signals through the type I activin receptor ACVRL1, engaging with the TGF-beta coreceptor endoglin/ENG to influence endothelial cells via SMAD1 signaling. This protein plays a critical role in vascular development and homeostasis.
Therapeutic significance:
Linked to Telangiectasia, hereditary hemorrhagic, 5, a vascular dysplasia causing blood vessel dilation and arteriovenous malformations, Growth/differentiation factor 2's involvement in angiogenesis inhibition positions it as a key target for therapeutic intervention in vascular and angiogenesis-related diseases.